Galecto Inc
GLTO27.170USD
+1.170+4.50%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
36.06MMarket Cap
LossP/E TTM
More Details of Galecto Inc Company
Galecto, Inc. is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. It is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
Galecto Inc Info
Ticker SymbolGLTO
Company nameGalecto Inc
IPO dateOct 29, 2020
CEOSchambye (Hans T)
Number of employees5
Security typeOrdinary Share
Fiscal year-endOct 29
Address75 State Street
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02109
Phone14570705210
Websitehttps://galecto.com/
Ticker SymbolGLTO
IPO dateOct 29, 2020
CEOSchambye (Hans T)
Company Executives of Galecto Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Julianne Bruno
Ms. Julianne Bruno
Independent Director
Independent Director
8.03K
--
Mr. Garrett Winslow
Mr. Garrett Winslow
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
1.43K
+41.63%
Ms. Lori Firmani
Ms. Lori Firmani
Interim Chief Financial Officer
Interim Chief Financial Officer
692.00
+48.82%
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Director
Independent Director
192.00
--
Dr. Chris W. Cain, Ph.D.
Dr. Chris W. Cain, Ph.D.
Independent Director
Independent Director
--
--
Mr. Peter Harwin
Mr. Peter Harwin
Independent Director
Independent Director
--
--
Mr. Matthew (Matt) Kronmiller
Mr. Matthew (Matt) Kronmiller
Executive Vice President of Strategy, Chief Business Officer
Executive Vice President of Strategy, Chief Business Officer
--
--
Dr. Jayson D.A. Dallas, M.D.
Dr. Jayson D.A. Dallas, M.D.
Independent Director
Independent Director
--
--
Dr. Carl M. Goldfischer, M.D.
Dr. Carl M. Goldfischer, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Hans T. Schambye, M.D., Ph.D.
Dr. Hans T. Schambye, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Julianne Bruno
Ms. Julianne Bruno
Independent Director
Independent Director
8.03K
--
Mr. Garrett Winslow
Mr. Garrett Winslow
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
1.43K
+41.63%
Ms. Lori Firmani
Ms. Lori Firmani
Interim Chief Financial Officer
Interim Chief Financial Officer
692.00
+48.82%
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Director
Independent Director
192.00
--
Dr. Chris W. Cain, Ph.D.
Dr. Chris W. Cain, Ph.D.
Independent Director
Independent Director
--
--
Mr. Peter Harwin
Mr. Peter Harwin
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Dec 9
Updated: Tue, Dec 9
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Ikarian Capital LLC
17.94%
Fidelity Management & Research Company LLC
15.00%
Point72 Asset Management, L.P.
6.28%
Goldfischer (Carl S)
2.63%
Geode Capital Management, L.L.C.
2.33%
Other
55.81%
Shareholders
Shareholders
Proportion
Ikarian Capital LLC
17.94%
Fidelity Management & Research Company LLC
15.00%
Point72 Asset Management, L.P.
6.28%
Goldfischer (Carl S)
2.63%
Geode Capital Management, L.L.C.
2.33%
Other
55.81%
Shareholder Types
Shareholders
Proportion
Hedge Fund
28.22%
Investment Advisor
15.72%
Individual Investor
3.57%
Investment Advisor/Hedge Fund
2.33%
Venture Capital
1.85%
Research Firm
1.24%
Other
47.06%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
44
164.38K
12.40%
-149.96K
2025Q2
59
237.90K
17.96%
-274.68K
2025Q1
62
239.03K
18.78%
-252.12K
2024Q4
60
217.43K
16.55%
-284.28K
2024Q3
59
203.99K
16.06%
-298.69K
2024Q2
60
348.76K
31.45%
-134.50K
2024Q1
63
345.52K
32.40%
-164.48K
2023Q4
60
341.29K
32.01%
-179.28K
2023Q3
64
397.38K
37.18%
-170.79K
2023Q2
66
515.37K
50.18%
-71.94K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Goldfischer (Carl S)
41.96K
3.17%
+1.00
+0.00%
Apr 15, 2025
Geode Capital Management, L.L.C.
9.29K
0.7%
--
--
Aug 31, 2025
Danmarks Eksport- og Investeringsfond
29.52K
2.23%
-29.52K
-50.00%
Sep 30, 2024
Renaissance Technologies LLC
14.54K
1.1%
-800.00
-5.21%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Date
Type
Ratio
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
Aug 28, 2024
Merger
25→1
FAQs
Who are the top five shareholders of Galecto Inc?
The top five shareholders of Galecto Inc are:
Goldfischer (Carl S) holds 41.96K shares, accounting for 3.17% of the total shares.
Geode Capital Management, L.L.C. holds 9.29K shares, accounting for 0.70% of the total shares.
Danmarks Eksport- og Investeringsfond holds 29.52K shares, accounting for 2.23% of the total shares.
Renaissance Technologies LLC holds 14.54K shares, accounting for 1.10% of the total shares.
Goldfischer (Carl S) holds 41.96K shares, accounting for 3.17% of the total shares.
Geode Capital Management, L.L.C. holds 9.29K shares, accounting for 0.70% of the total shares.
Danmarks Eksport- og Investeringsfond holds 29.52K shares, accounting for 2.23% of the total shares.
Renaissance Technologies LLC holds 14.54K shares, accounting for 1.10% of the total shares.
What are the top three shareholder types of Galecto Inc?
The top three shareholder types of Galecto Inc are:
Ikarian Capital LLC
Fidelity Management & Research Company LLC
Point72 Asset Management, L.P.
Ikarian Capital LLC
Fidelity Management & Research Company LLC
Point72 Asset Management, L.P.
How many institutions hold shares of Galecto Inc (GLTO)?
As of 2025Q3, 44 institutions hold shares of Galecto Inc, with a combined market value of approximately 164.38K, accounting for 12.40% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -5.56%.
What is the biggest source of revenue for Galecto Inc?
In --, the -- business generated the highest revenue for Galecto Inc, amounting to -- and accounting for --% of total revenue.
